Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)Seeking Alpha • 01/18/25
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/07/25
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall StreetThe Motley Fool • 12/15/24
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 TodayThe Motley Fool • 12/14/24
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% HigherThe Motley Fool • 12/02/24
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsInvestors Business Daily • 11/14/24
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And OpdivoBenzinga • 11/04/24
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil SalesZacks Investment Research • 10/31/24
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024Business Wire • 10/30/24